Core Connotation and Technical Value of Automated Closed Solid-Phase Peptide Synthesis

Automated closed solid-phase peptide synthesis is a production mode based on solid-phase peptide synthesis (SPPS). It integrates automated control technology, closed reaction systems, and intelligent monitoring and regulation modules to realize fully automated operation, closed operation, and full-process controllable management of the entire peptide synthesis workflow, including resin activation, amino acid coupling, deprotection, washing, cleavage, and purification. Its core characteristics are unmanned intervention, closed isolation, precise control, and efficient scalability. Different from traditional open and semi-automated synthesis, it not only solves the core pain points of conventional production but also meets the industrialized, standardized, and compliant production requirements of peptide drugs. Its technical value is mainly reflected in three dimensions.

First, it resolves pain points in safety and compliance. Peptide synthesis uses corrosive and irritating reagents such as piperidine and trifluoroacetic acid (TFA). Traditional open operations easily cause reagent leakage, which endangers operator health and may lead to environmental pollution. Meanwhile, open production is prone to impurity introduction, which affects product purity and makes it difficult to meet GMP standards. The fully closed design of the automated closed system isolates reagent storage, delivery, reaction, and waste discharge throughout the process. It protects occupational safety, avoids external impurities, and enables full-process traceability, complying with regulatory requirements including NMPA and FDA, laying a foundation for clinical application and commercialization of peptide drugs.

Second, it improves production efficiency and product consistency. Traditional solid-phase peptide synthesis relies on manual labor, requiring repeated manual intervention in amino acid coupling, deprotection, washing, and other steps. This is not only time- and labor-consuming but also leads to large batch-to-batch variations in purity and yield due to human error—especially in the synthesis of long-chain and complex modified peptides, where the limitations of manual operation are more prominent. Through the linkage of programmable logic controller (PLC), host computer software, and DCS system, the automated closed system realizes full-process automatic operation. It precisely controls key parameters such as reaction temperature, time, reagent dosage, and stirring speed, reduces human error, and greatly improves batch-to-batch consistency. Meanwhile, the automated system supports parallel synthesis of multiple sequences and batches, shortening the single amino acid coupling cycle to within 15 minutes and completing the synthesis of the standard 10-peptide ACP (including cleavage) in 3 hours. Production efficiency is 5–10 times higher than manual operation, effectively solving the industry bottleneck of lacking mature automated solutions for solid-phase peptide synthesis at scales above 500 L.

Third, it supports large-scale and intelligent transformation. The industrial translation of peptide drugs from laboratory to clinic depends on large-scale production. Traditional semi-automated synthesis equipment is mostly limited to laboratory-scale and pilot-scale production and cannot achieve kilogram- or ton-level manufacturing. In contrast, the automated closed solid-phase synthesis system supports flexible scaling from milligram and gram levels to kilogram and ton levels. Through equipment scale-up and process optimization, it meets production demands at different stages including clinical sample preparation and commercial manufacturing. As examples, Asymchem has successfully scaled up solid-phase synthesizers, with new structures patented and planned for further expansion to 2000 L; Chutian Technology has launched a 3000 L automated solid-phase peptide synthesis solution, achieving a breakthrough in large-scale production. Furthermore, the system can be deeply integrated with AI and big data analytics to optimize reaction parameters, predict synthesis risks, and realize intelligent regulation of production, driving peptide manufacturing from experience-driven to data-driven.